ID   SR DU-145
AC   CVCL_4901
SY   SR DU 145; SR DU145
DR   cancercelllines; CVCL_4901
DR   Wikidata; Q54955623
RX   PubMed=9923549;
RX   PubMed=15643172;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:45906; Suramin.
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); ClinVar=VCV001786615; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Brain; UBERON=UBERON_0000955.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0105 ! DU145
SX   Male
AG   69Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 21
//
RX   PubMed=9923549; DOI=10.1007/s002800050884;
RA   Church D., Zhang Y.-L., Rago R., Wilding G.;
RT   "Efficacy of suramin against human prostate carcinoma DU145 xenografts
RT   in nude mice.";
RL   Cancer Chemother. Pharmacol. 43:198-204(1999).
//
RX   PubMed=15643172; DOI=10.1097/01.ju.0000141580.30910.57;
RA   Sobel R.E., Sadar M.D.;
RT   "Cell lines used in prostate cancer research: a compendium of old and
RT   new lines -- part 1.";
RL   J. Urol. 173:342-359(2005).
//